These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 3508655)

  • 21. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
    Beck M; Smerdel S; Dedić I; Delimar N; Rajninger-Miholic M; Juzbasić M; Manhalter T; Vlatković R; Borcić B; Mihajić Z
    Dev Biol Stand; 1986; 65():95-100. PubMed ID: 3556780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
    Narayan KM; Moffat MA
    Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination.
    Lerman SJ; Bollinger M; Brunken JM
    Pediatrics; 1981 Jul; 68(1):18-22. PubMed ID: 7017582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
    Christenson B; Böttiger M
    Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
    JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test.
    Fedová D; Brůcková M; Plesník V; Slonim D; Sejda J; Svandová E; Kubínová I
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(4):409-22. PubMed ID: 3429853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-gamma production closely related to antibody production in lymphocyte cultures stimulated with mumps virus.
    Nakayama T; Unno S; Urano T; Osano M; Sasaki K; Makino S
    Kitasato Arch Exp Med; 1990 Sep; 63(2-3):99-106. PubMed ID: 2128947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to measles-mumps-rubella vaccine in children on dialysis.
    Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
    Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saliva antibody testing and vaccination in a mumps outbreak.
    Ramsay ME; Brown DW; Eastcott HR; Begg NT
    CDR (Lond Engl Rev); 1991 Aug; 1(9):R96-8. PubMed ID: 1669793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G; Peña B; Marimón JM; Pérez-Trallero E
    Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age.
    Singh R; John TJ; Cherian T; Raghupathy P
    Indian J Med Res; 1994 Oct; 100():155-9. PubMed ID: 7851964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two doses of measles mumps rubella (MMR) vaccine.
    Kuno-Sakai H; Ozaki K; Kimura M
    Acta Paediatr Jpn; 1989 Dec; 31(6):690-7. PubMed ID: 2516395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seroconversion and reaction of vaccines, rubella--mumps and measles--rubella--mumps combined.
    Khanjanasthiti P; Jayavasu J; Kashemsant C; Dhanamitta S; Prapattong S
    J Med Assoc Thai; 1978 Sep; 61(9):536-43. PubMed ID: 690542
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
    Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
    Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
    Just M; Berger R; Glück R; Wegmann A
    Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
    Gonçalves G; Tavares F; de Andrade HR
    Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
    Trier H; Rønne T
    Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine.
    Topal B; Kanra G; Ceyhan M
    Turk J Pediatr; 1991; 33(1):13-8. PubMed ID: 1844171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.